Erin E. Crotty

Jan 7, 2025 | nature.com | Nicholas A. Vitanza |Michelle Choe |wenjun Huang |Madison Beam |ashley wilson |Erin E. Crotty | +6 more

AbstractDiffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG.